Bosh sahifaHPX • FRA
add
Hisamitsu Pharmaceutical Co Inc
Yopilish kursi
25,60 €
Kunlik diapazon
25,80 € - 25,80 €
Yillik diapazon
21,00 € - 28,80 €
Bozor kapitalizatsiyasi
364,25 mlrd JPY
Oʻrtacha hajm
6,00
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
TYO
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(JPY) | avg, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 39,65 mlrd | 13,66% |
Joriy xarajat | 18,75 mlrd | 17,95% |
Sof foyda | 4,31 mlrd | -1,33% |
Sof foyda marjasi | 10,87 | -13,18% |
Har bir ulushga tushum | — | — |
EBITDA | 6,35 mlrd | 20,49% |
Amaldagi soliq stavkasi | 28,38% | — |
Balans
Jami aktivlari
Jami passivlari
(JPY) | avg, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 122,74 mlrd | -13,22% |
Jami aktivlari | 350,48 mlrd | 1,79% |
Jami passivlari | 74,55 mlrd | 7,74% |
Umumiy kapital | 275,92 mlrd | — |
Tarqatilgan aksiyalar | 73,34 mln | — |
Narxi/balansdagi bahosi | 0,01 | — |
Aktivlardan daromad | 3,52% | — |
Kapitaldan daromad | 4,46% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(JPY) | avg, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | 4,31 mlrd | -1,33% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
The Hisamitsu Pharmaceutical Co., Inc., headquartered in Saga and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology since the introduction of its original line of patches in 1903.
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration. Wikipedia
Tashkil etilgan
1847
Bosh ofis
Sayt
Xodimlar soni
2 759